Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:264-270
Published online before print January 10, 2005, doi: 10.1161/01.CIR.0000153338.47507.83
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/3/264    most recent
01.CIR.0000153338.47507.83v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kikuchi, K.
Right arrow Articles by Donahue, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kikuchi, K.
Right arrow Articles by Donahue, J. K.
Related Collections
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow Ion channels/membrane transport
Right arrow Gene therapy

(Circulation. 2005;111:264-270.)
© 2005 American Heart Association, Inc.


Arrhythmia/Electrophysiology

Targeted Modification of Atrial Electrophysiology by Homogeneous Transmural Atrial Gene Transfer

Kan Kikuchi, MD; Amy D. McDonald, BS; Tetsuo Sasano, MD, PhD; J. Kevin Donahue, MD

From the Johns Hopkins University School of Medicine, Baltimore, Md.

Correspondence to J. Kevin Donahue, MD, Johns Hopkins University School of Medicine, Ross 844, 720 N Rutland Ave, Baltimore, MD 21205. E-mail kdonahue{at}jhmi.edu

Received May 28, 2004; revision received September 13, 2004; accepted October 13, 2004.

Background— Safe and effective myocardial gene transfer remains elusive. Heterogeneous ventricular gene delivery has been achieved in small mammals but generally with methods not readily transferable to the clinic. Atrium-specific gene transfer has not yet been reported. We hypothesized that homogeneous atrial gene transfer could be achieved by direct application of adenoviral vectors to the epicardial surface, use of poloxamer gel to increase virus contact time, and mild trypsinization to increase virus penetration.

Methods and Results— We "painted" recombinant adenovirus encoding the reporter gene Escherichia coli ß-galactosidase directly onto porcine atria. Investigational variables included poloxamer use, trypsin concentration, and safety. Using the painting method, we modified the atrial phenotype with an adenovirus expressing HERG-G628S, a long-QT-syndrome mutant. Our results showed that application of virus with poloxamer alone resulted in diffuse epicardial gene transfer with negligible penetration into the myocardium. Dilute trypsin concentrations allowed complete transmural gene transfer. After trypsin exposure, echocardiographic left atrial diameter did not change. Left atrial function decreased on postoperative day 3 but returned to baseline by day 7. Tissue tensile strength was affected only in the 1% trypsin group. HERG-G628S gene transfer prolonged atrial action potential duration and refractory period without affecting ventricular electrophysiology.

Conclusions— We show complete transmural atrial gene transfer by this novel painting method. Adaptation of the method could allow application to other tissue targets. Use with functional proteins in the atria could cure or even prevent diseases such as atrial fibrillation or sinus node dysfunction.


Key Words: arrhythmia • gene therapy • electrophysiology • atrium




This article has been cited by other articles:


Home page
Circ. Res.Home page
W. Li and R. L. Silverstein
Biological Surgery: Synergetic Angiogenic Therapy Using Coadministration of Two Progenitor Cell Populations
Circ. Res., September 26, 2008; 103(7): 684 - 686.
[Full Text] [PDF]


Home page
EuropaceHome page
I. Savelieva and J. Camm
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
Europace, June 1, 2008; 10(6): 647 - 665.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. R. Ehrlich, P. Biliczki, S. H. Hohnloser, and S. Nattel
Atrial-Selective Approaches for the Treatment of Atrial Fibrillation
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 787 - 792.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. E. Lehnart, M. J. Ackerman, D. W. Benson Jr, R. Brugada, C. E. Clancy, J. K. Donahue, A. L. George Jr, A. O. Grant, S. C. Groft, C. T. January, et al.
Inherited Arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases Workshop Consensus Report About the Diagnosis, Phenotyping, Molecular Mechanisms, and Therapeutic Approaches for Primary Cardiomyopathies of Gene Mutations Affecting Ion Channel Function
Circulation, November 13, 2007; 116(20): 2325 - 2345.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Koide, M. Okazaki, M. Tamura, K. Ozumi, H. Takatsu, F. Kamezaki, A. Tanimoto, H. Tasaki, Y. Sasaguri, Y. Nakashima, et al.
PTEN reduces cuff-induced neointima formation and proinflammatory cytokines
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2824 - H2831.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. K. Kapur, C. B. Deming, S. Kapur, C. Bian, H. C. Champion, J. K. Donahue, D. A. Kass, and J. J. Rade
Hemodynamic Modulation of Endocardial Thromboresistance
Circulation, January 2, 2007; 115(1): 67 - 75.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. V. Podgoreanu and J. P. Mathew
Prophylaxis Against Postoperative Atrial Fibrillation: Current Progress and Future Directions
JAMA, December 28, 2005; 294(24): 3140 - 3142.
[Full Text] [PDF]